MannKind/$MNKD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About MannKind

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Ticker

$MNKD
Sector
Primary listing

Employees

405

MannKind Metrics

BasicAdvanced
$1.6B
49.35
$0.11
1.02
-

What the Analysts think about MannKind

Analyst ratings (Buy, Hold, Sell) for MannKind stock.

Bulls say / Bears say

Afrezza net sales climbed 13% year-over-year to $18.3 million in Q2 2025, underscoring growing commercial adoption of the inhaled insulin platform. (GuruFocus)
As of June 30, 2025, MannKind held $201.2 million in cash, cash equivalents, and investments, providing substantial runway to fund ongoing and upcoming clinical programs. (GuruFocus)
The company filed a supplemental BLA for Afrezza in pediatric patients with an FDA review decision expected in early Q4 2025, positioning MannKind to expand its addressable market to children and adolescents. (GuruFocus)
Shares dropped approximately 12% after Q2 results showed revenues of $76.5 million missed consensus estimates, reflecting investor concerns over growth execution. (Investing.com)
Collaborations and services revenue fell 12% and V-Go sales declined 8% in Q2 2025, highlighting the company’s reliance on a narrow product portfolio and potential volatility in non-core segments. (Investing.com)
Selling, general, and administrative expenses surged 31% year-over-year in Q2 2025, pressuring operating leverage as MannKind ramps up commercial and clinical infrastructure. (GuruFocus)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.

MannKind Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

MannKind Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MNKD

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs